Alopecia Treatment Market Size, Share & Trends Analysis Report By Drug Class (Minoxidil, Finasteride, Other Drug), By Indication (Androgenic Alopecia, Alopecia Areata, Alopecia Totalis, Others), By Distribution Channels (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, Online Pharmacies) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Alopecia Treatment Market Size

The global alopecia treatment market size was valued at USD 3.21 billion in 2022 And is projected to reach USD 4.6 billion by 2031, growing at a CAGR of 4.1% during the forecast period (2023–2031).

The increase in chronic diseases and the surge in the global geriatric population promote market growth. Hair loss from the head or body is called alopecia, often known as hair loss or baldness. The illness can affect anyone, male or female, of any age. There are five main alopecia types: telogen effluvium, androgenic alopecia, alopecia areata, alopecia totalis, and cicatricial alopecia. An autoimmune condition called alopecia areata damages the hair follicles, resulting in hair loss or breakage and, eventually, total baldness. Hormonal changes, inherited conditions, radiation therapy to the head, stress, and specific drugs and supplements are among the factors that contribute to male-pattern alopecia and female-pattern alopecia.

Alopecia treatment is important in modern medicine because it promotes hair growth and prevents loss. Minoxidil, finasteride, 5-alpha reductase inhibitors, corticosteroids, and cyclosporine can treat hair loss. Surgical alopecia therapies include laser therapy, scalp reduction, and hair transplantation.

Alopecia Treatment Market Growth Factors

Increase in Chronic Diseases

It is expected that disorders like severe hair loss will become more prevalent due to chronic diseases like cancer, hypertension, rheumatoid arthritis, depression, and others. For instance, the American Cancer Society, Inc. estimated that in the United States in 2018, there were around 1,735,350 new cancer cases. As a result, the market for alopecia treatments is projected to grow as cancer incidence rises. Another factor driving the market's expansion is the rising prevalence of polycystic ovary syndrome (PCOS) among women. The imbalance of hormones caused by this condition damages the hair follicles, which is likely to cause hair loss and increase demand for medications to treat alopecia. For instance, the American Academy of Family Physicians reports that in 2016, PCOS impacted over 7% of American women of reproductive age.

Surge in Global Geriatric Population

One of the key factors propelling the market for alopecia treatments is the rapid rise in the elderly population. The number of older adults worldwide has substantially increased, making them more susceptible to alopecia disorders such as androgenic alopecia, alopecia areata, alopecia totalis, and others. According to data from the U.S. Census Bureau, the senior population in the United States made up 14.9% of the total population in 2015. By 2035, this figure is projected to rise to 78.0 million. Additionally, as the prevalence of chronic diseases rises at an alarming rate worldwide, the growing geriatric population is increasing stress on healthcare systems worldwide. Thus, the increasing number of older adults worldwide is driving up demand for alopecia treatment solutions.

Market Restraining Factors

Poor Demand in Underdeveloped Countries

It is challenging for the market for alopecia treatments to flourish in impoverished countries like Asia and Africa due to lack of funding, low income, pharmaceutical businesses, cutting-edge manufacturing procedures, and other issues. Additionally, the market's growth is constrained in developing nations like Ethiopia, Afghanistan, and Guinea due to insufficient government support for using alopecia treatment drugs and experienced professionals.

Market Opportunities

Growth Opportunities in Emerging Markets

The availability of better pharmaceutical industry infrastructure, development in pharmaceutical industries, and rise in demand for alopecia treatment pharmaceuticals likely propel the alopecia treatment market's expansion in unexplored, emerging economies. The demand for improved advanced manufacturing systems is increasing, and the government is making major investments to upgrade the healthcare infrastructure, causing the healthcare business in emerging economies to grow significantly. Additionally, pharmaceutical businesses are concentrated in rising areas like China, India, and others, which will help this industry expand even faster.

Regional Insights

North America: Dominant region with 3.6% market share

North America is the most significant global alopecia treatment market shareholder and is estimated to exhibit a CAGR of 3.6% over the forecast period. The rise influences the development of the North American market in alopecia disorders such as androgenic alopecia, alopecia areata, alopecia totalis, and others, the availability of cutting-edge healthcare facilities with skilled medical staff, and the increase in R&D centers. The Pharmaceutical Research and Manufacturers Association (PhRMA) claims that American companies carry out more than half of the world's pharmaceutical R&D and own the intellectual property rights to most new medications.

Moreover, growth in this industry is attributed to the creation of technologically sophisticated treatment products, an increase in the use of alopecia treatment products to treat hair loss, a rise in patient awareness of alopecia treatment, and an increase in chronic diseases like cancer, arthritis, and hypertension. The expansion of the alopecia treatment market in the U.S. was further aided by the Centers for Medical and Medicaid Services (CMS) favorable payment policy. This reimbursement system gives hospitals financial incentives to enhance treatment and cut costs.

Europe: Fastest growing region with the highest CAGR

Europe is anticipated to exhibit a CAGR of 4% over the forecast period. The market in this region is expected to grow as a result of factors including rising androgenetic alopecia, alopecia areata, and other cases, unhealthy diets, hormonal imbalance, and the dominance of key players like GlaxoSmithKline Plc, Vitabiotics Ltd., Vita-Cos-Med Klett-Loch GmbH, among others. Europe's other significant growth factor is increased patient awareness of alopecia treatments.

Additionally, the current regulatory framework commercially markets alopecia treatment items in the European Union (E.U.) with the Conformité Européene (C.E.) label. This rule aims to dramatically improve patient safety and public health through consistent application and continued monitoring of product performance across the E.U. Increased awareness of treatments for hair loss conditions, a large population base, a rise in disposable income, an increase in cases of male- and female-pattern baldness, and a rise in demand for new emerging products are some of the factors driving the growth of the European market for alopecia treatments. Due to major players and the availability of sophisticated healthcare infrastructure with cutting-edge technologies, the market is predicted to rise significantly in Germany, France, and the U.K.

Asia-Pacific has emerged as one of the fastest-growing regions in the global market. The high population base, high disposable incomes, increased patient awareness of alopecia therapy, and surge in demand for alopecia treatment products all contribute to this region's market growth. India and China are the most populous nations in the Asia-Pacific region, with a dense population overall. These countries have enormous populations and a high male and female pattern baldness rate.

Furthermore, Asia-Pacific is predicted to have the fastest market growth during the forecast period due to improvements in healthcare infrastructure, an increase in the number of hospitals with cutting-edge medical equipment, the increasing R&D industry, healthcare reforms, and technological breakthroughs. To exploit market opportunities with high growth rates, leading manufacturers increasingly focus on expanding their geographic reach in developing Asia-Pacific nations. China is also anticipated to grow at the fastest CAGR throughout the projected period due to its sizable population, high demand for advanced medical facilities, and growing RandD efforts in the pharma sector.

In LAMEA, because there aren't many hospitals with cutting-edge medical equipment and skilled staff, the market for treating alopecia is still in its infancy. LAMEA is a developing market that is anticipated to offer major players significant growth prospects as the target population grows, alopecia treatment becomes more widely known, and the healthcare system is improved. Additionally, the rising number of alopecia patients in LAMEA has accelerated the use of alopecia treatments, propelling the market's expansion.

Alopecia Treatment Market Segmentation Analysis

By Drug Class

the market is bifurcated into minoxidil, finasteride, and other drugs. The minoxidil segment dominates the global market and is projected to exhibit a CAGR of 4% over the forecast period. Male-pattern hair loss can be treated with the medication minoxidil, which also promotes hair growth. It is a generic drug that is also sold over the counter. It is frequently given to the affected scalp area because it encourages cell multiplication and hair growth. Additionally, it works well in patients with androgenic alopecia to encourage hair growth. Additionally, it supports existing hair follicles and maintains any experienced hair regrowth.

By Indication

The market is segmented into androgenic alopecia, alopecia areata, alopecia totalis, and others. Androgenic alopecia disorders dominate the global market and are predicted to exhibit a CAGR of 4.5% during the forecast period. A hereditary condition known as androgenic alopecia can affect both sexes. The gradual transformation of terminal hairs into fuzzy hairs, then vellus hairs, can be used to identify this condition. Male-pattern baldness is a problem that affects men and can manifest as early as adolescence. Female pattern baldness is a condition that can affect women beyond the age of 40 or later. Increased hair growth and halting the progression of hair thinning are the two main objectives of treating androgenic alopecia. Finasteride and minoxidil are two medications with FDA approval that are prescribed for androgenetic alopecia.

Androgenic alopecia accounts for a significant portion of the global market's revenue. It is anticipated to grow significantly over the coming years due to rising androgenic alopecia prevalence, increased adoption of androgenic alopecia treatment drugs, technological advancements, innovations in healthcare infrastructure, and rising demand for alopecia treatment medications.

By Distribution Channels

The market is bifurcated into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. The drug stores and retail pharmacies segment owns the highest market share and is predicted to exhibit a CAGR of 3.5% over the forecast period. Drug stores and retail pharmacies are businesses that sell and dispense pharmaceuticals. Additionally, drug stores may offer cosmetics, first-aid kits, prescription prescriptions, over-the-counter medicines, and nonprescription treatments. Retail pharmacists also give patients advice on over-the-counter medications and other health information. Due to their convenience and the significant revenue contribution that pharmacy stores and retail pharmacies provide, these segments are expected to dominate the market during the projection period.

Recent Developments

• June 2023- Pfizer's LITFULOTM (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata has received FDA approval. The medication, known by the brand name Litfulo, has been approved for use in patients with severe alopecia areata (A.A.), a disorder in which the immune system assaults hair follicles and results in hair loss that frequently occurs in clumps, who are 12 years of age and older.
• June 2023- In a Phase I trial to treat androgenic alopecia, often known as male-pattern baldness, oliX Pharmaceuticals has administered its RNAi treatment, OLX72021, to its first patient.